Journal of Clinical Trials
Open Access
ISSN: 2167-0870
ISSN: 2167-0870
Department of Medical Affairs, Clinical Director, Kibow Biotech Inc, Pennsylvania, USA
Dr. Emmanuel Anteyi is currently working in Department of Medical Affairs, Kibow Biotech Inc, Pennsylvania, USA. He has published numerous research papers and articles in reputed journals and has various other achievements in the related studies. He has extended his valuable service towards the scientific community with his extensive research work.
Research Article
A Double-Blind Randomized, Placebo-Controlled Phase 2 Clinical Trial to Evaluate Safety and Efficacy of US APR 2020 in Subjects with Chronic
Kidney Disease Stage IV
Author(s): Emmanuel Anteyi*, Pari Ranganathan, Usha Vyas, Qiannan Zhao and Nataraja Ranganathan
Background: CKD is a common public health problem affecting over 200 million people worldwide. The United States
accounted for about 30 million CKD patients with high morbidity, mortality and enormous health costs. Despite advancement
in treatment options of risk factors for CKD like hypertension and diabetes, progression to end stage kidney disease and
complications remain high. Observations of gut dysbiosis associated with progressive kidney disease, systemic inflammation
and uremic toxin retention led to trial use of probiotics in restoring gut microbiome to ameliorate CKD. Studies have shown
benefits in restoring gut microbiota with probiotics retarded progression, reduced uremic toxins, and improved quality of life
in CKD. This clinical trial is to evaluate safety and efficacy of probiotic formulation US APR 2020 in patients with CKD stage
4 .. View More»
DOI:
10.35248/2167-0870.21.11.468